Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLORAL: Long-term Safety and Efficacy of Etavopivat in Sickle Cell Disease or Thalassaemia
NCT06609226Phase 3Recruiting
- Sponsor
- Novo Nordisk
- Start
- Jan 2025
- Primary completion
- Dec 2030
- Modality
- Small Molecules
- Countries
- 17
01
Overview
A Phase 3 trial of etavopivat in sickle cell disease (SCD), thalassemia, sponsored by Novo Nordisk. Started Jan 2025; status: recruiting.
02
Drugs
etavopivat
03
Conditions
sickle cell disease (SCD)thalassemia
Beyond the preview
Go deeper on NCT06609226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06609226.